Menu Search
Equities

Nuo Therapeutics Inc

AURX:QBB

Nuo Therapeutics Inc

Actions
  • Price (USD)0.80
  • Today's Change0.01 / 1.27%
  • Shares traded5.00k
  • 1 Year change+33.33%
  • Beta1.0312
Data delayed at least 15 minutes, as of Nov 08 2024 19:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Nuo Therapeutics Inc grew revenues 442.12% from 112.25k to 608.53k while net income improved from a loss of 3.17m to a smaller loss of 3.17m.
Gross margin79.48%
Net profit margin-261.78%
Operating margin-261.80%
Return on assets-191.94%
Return on equity-503.61%
Return on investment-381.40%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Nuo Therapeutics Inc fell by 1.18m. Cash Flow from Financing totalled 2.00m or 328.25% of revenues. In addition the company used 3.17m for operations while cash used for investing totalled 7.24k.
Cash flow per share-0.0617
Price/Cash flow per share--
Book value per share0.0132
Tangible book value per share0.0132
More ▼

Balance sheet in USDView more

Nuo Therapeutics Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio1.70
Quick ratio1.39
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.